Celltrion Launches Direct Sales of Three Oncology Drugs in Spain

Successful Bid for CSC Overseeing 25 Public Hospitals
"Continuous Strengthening of Sales Competitiveness Centered on Local Subsidiaries"

Celltrion announced on May 14 that, following discussions with its Spanish distribution partner Kern Pharma, it has established a direct sales system led by its local subsidiary in Spain starting this month.

Celltrion's Spanish subsidiary will begin direct sales with three oncology drugs currently sold in the local market: Truxima (ingredient: rituximab), Herzuma (ingredient: trastuzumab), and Vegzelma (ingredient: bevacizumab).

Previously, Celltrion's Spanish subsidiary participated in a CSC consortium tender held recently in Catalonia, securing a contract to supply Truxima and Herzuma to the consortium for approximately four years, until 2029. CSC is one of Spain's major tendering organizations and oversees the supply of pharmaceuticals to 25 public hospitals in Catalonia.

In December last year, Celltrion launched Stekima (ingredient: ustekinumab) in Portugal, marking the start of its direct sales operations there. Beginning last month, the company expanded its direct sales products to cover its entire portfolio.

Celltrion plans to accelerate its penetration of the European market through a direct sales system led by its local subsidiaries in the five major European countries.

Additionally, in December last year, Celltrion began direct sales in Portugal with the launch of Stekima (ingredient: ustekinumab). Since last month, after discussions with its distribution partner, the company has expanded its direct sales products to include its entire portfolio, such as autoimmune disease treatments and oncology drugs.

Celltrion aims to achieve rapid growth by continuously seeking market expansion opportunities, including successful bids, in Spain and Portugal. In particular, as the direct sales system becomes increasingly stable, the company expects to secure a competitive advantage in tenders by implementing more strategic pricing policies.

Kang Seokhoon, head of Celltrion's Spanish and Portuguese subsidiaries, stated, "Based on the marketing experience and expertise we have accumulated locally, we will focus on stabilizing distribution networks in new direct sales regions, while continuously strengthening our sales competitiveness centered on our local subsidiaries."